SYMPOSIUM OVERVIEW

The Optimizing Breast Cancer Therapy: Integrating Biologic Approaches Into Everyday Practice satellite to the 2006 San Antonio Breast Cancer Symposium is designed to update medical oncologists on the latest developments in the use of biologic therapies in the treatment of breast cancer and how to integrate these findings into their everyday practices. This symposium will discuss the integration of targeted therapies into current treatment regimens, including inhibitors of the VEGF and HER2 signaling pathways as well as next-generation targeted agents at different stages of clinical development. Patient selection and treatment optimization will also be covered. A panel discussion will allow participants the opportunity to receive input on clinically relevant questions.

TARGET AUDIENCE

This satellite symposium is designed to be of high clinical utility to medical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity. Fellows, nurses, and pharmacists in oncology are also invited to attend.

CME ACCREDITATION AND DESIGNATION

Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

At the conclusion of this symposium, you should be able to:

• Discuss the current clinical data on monoclonal antibodies targeting VEGF in advanced breast cancer, including combinations with cytotoxic chemotherapy and potential predictive markers for response
• List the agents undergoing investigation in breast cancer that inhibit angiogenesis and vasculogenesis and desribe their targets
• Evaluate emerging treatment paradigms, including combinations of hormonal therapies and cytotoxic chemotherapies with biologic/targeted agents in early-stage breast cancer
• Assess considerations for individualizing therapy for patients with breast cancer, including improving the therapeutic index and selecting patients for specific therapeutic approaches
• Examine the rationale for novel antibody-based approaches to the treatment of metastatic breast cancer

ACKNOWLEDGEMENT

This activity is supported by an educational grant from:

Genentech BioOncology